LabCorp® (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care. Through its two business segments, LabCorp Diagnostics and Covance Drug Development, the company provides comprehensive clinical laboratory and end-to-end drug development services.

With nearly 65,000 employees worldwide, the company’s mission is to improve health and improve lives by delivering world-class diagnostics, accelerating the availability of innovative medicines to patients, and using technology to change the way care is delivered. LabCorp serves hundreds of thousands of customers around the world and provides diagnostic, drug development, and technology-enabled solutions for more than 160 million patient encounters per year. It reported net revenues of more than $11.5 billion in 2019.

With roots going back more than 100 years, LabCorp has played a role in the evolving healthcare industry, which has fundamentally transformed how well, and how long, people live. As the healthcare system itself transforms and expectations rise, the company is increasingly involved in meeting the unique needs of patients. LabCorp understands that one size does not always fit all, as the future of healthcare is personal.

Headquartered in Burlington, North Carolina, LabCorp identifies its founding in 1969 and celebrated its 50th anniversary in 2019. It is listed on the New York Stock Exchange under the ticker symbol “LH” in 1995. Through a combination of organic growth and disciplined acquisitions, LabCorp has continually expanded and diversified its business offerings, technological expertise, geographic reach, revenue base, and financial growth opportunities.

Today, the company participates in drug discovery from discovery through commercialization; it is the go-to partner for the development, validation and commercialization of companion diagnostics, which are key drivers of precision medicine; it offers a growing menu of high-quality, high-value clinical laboratory tests; and, increasingly, it provides guidance to consumers and care providers about how to integrate drugs and diagnostics into patient care.

LabCorp serves a broad range of customers, including managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, CROs, and independent clinical laboratories. Leveraging the company’s deep scientific and therapeutic experience, cutting-edge technology, and considerable real-world data and patient intelligence, LabCorp customers can understand and respond to evolving patient needs with precision.

LabCorp is focused on creating practical innovations that enable targeted and tailored care and accelerate the path to high-quality outcomes. From making innovative genetic tests more accessible to helping develop the next generation of lifesaving drugs, LabCorp’s work is integral to improving the health and lives of the millions of individuals for whom we care each week.
LabCorp reports its business in two segments, LabCorp Diagnostics and Covance Drug Development.

LabCorp Diagnostics (LCD) offers a comprehensive menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the U.S. and Canada. The network is supported by a sophisticated information technology system, with more than 65,000 electronic interfaces to deliver test results, nimble and efficient logistics, and local labs offering rapid response testing. LCD also provides patient access points, strategically and conveniently located throughout the U.S., including nearly 2,000 patient service centers (PSCs) operated by the company and more than 6,000 in-office phlebotomists who are located in customer offices and facilities. The segment offers a growing menu of nearly 5,000 tests, including a wide range of clinical, anatomic pathology, genetic, and genomic tests. In addition to diagnostic testing, LCD offers a range of other testing services, including parentage and occupational and wellness testing for employers.

Covance Drug Development (CDD) provides end-to-end drug and medical device development services from early-stage research to clinical development and commercial market access. CDD provides a wide range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It has deep expertise in early development and clinical trials, supporting clinical trial activity in approximately 100 countries through its industry-leading central laboratory business, generating more safety and efficacy data to support drug approvals than any other company. CDD collaborated on more than 85% of the novel drugs approved by the FDA in 2019, including most of the novel rare and orphan disease drugs and novel oncology drugs. In addition, CDD has been involved in the development of all current top 50 drugs on the market as measured by sales revenue.

The combination of LCD’s and CDD’s core capabilities and scientific expertise enables the company to create compelling solutions for clients. The combination has contributed to LabCorp’s position as a market leader in the development and commercialization of companion and complementary diagnostics. LCD and CDD have been involved in the development of drugs and their associated companion diagnostics for more than 20 years, and together have supported more FDA-approved companion diagnostics than any other company.

LabCorp continues to be recognized for its reputation and leadership. Recent accolades include being named to FORTUNE magazine’s List of “World’s Most Admired Companies,” for two consecutive years; earning the highest achievable score on the Human Rights Campaign Foundation’s 17th annual scorecard on lesbian, gay, bisexual, transgender, and queer (LGBTQ) workplace equality and being designated as a Best Place to Work for LGBTQ Equality for the third year in a row; and seeing its CDD business awarded the 2019 Frost & Sullivan Asia-Pacific CRO Customer Value Leadership Award.